Efficacy and risk of rituximab in type II mixed cryoglobulinemia: a significant case report.
Massari
Marco
M
Infectious Disease Unit, Azienda Ospedaliera S. Maria Nuova, Reggio Emilia, Italy. massari.marco@asmn.re.it
Catania
Alberto
A
Magnani
Giacomo
G
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D003449:Cryoglobulinemia / Q000188:drug therapy*; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000209:etiology; D000069283:Rituximab; D013577:Syndrome; D014657:Vasculitis / Q000188:drug therapy
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab